MLYSMineralys Therapeutics, Inc.
$23.36-41% 1Y
$23.36
$21.9552 weeks$47.33
MLYS as reported
- Net income
- −$350M
Net income · +83% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$142M
Free cash flow · trailing twelve months to Q4 2025
- EPS
- −$4.19
EPS · +18% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$350M | +83% | Q2 2026 |
| EPS | −$4.19 | +18% | Q2 2026 |
| ROE | −35% | n/a | Q2 2026 |
| ROA | −32% | n/a | Q2 2026 |
| Free cash flow | −$142M | n/a | Q4 2025 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Mineralys Therapeutics, Inc. (MLYS) · Net incomeNet incomeMineralys Therapeutics, Inc. (MLYS)
On our screens:Most shorted stocks